Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (191-200 of 259) with videos related to

Pageof 26
Sort By:
Plos Medicine|July 3, 2019
Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker NetworkAndrée-Anne Grosset, Véronique Ouellet, Christine Caron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2018
Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate CancerMarine F Garrido, Nicolas J-P Martin, Matthieu Bertrand, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
The Journal of Clinical Investigation|December 18, 2019
Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor modelsLucia Nappi, Adeleke H Aguda, Nader Al Nakouzi, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
Plos One|July 15, 2015
Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 PatientsJames D Brooks, Wei Wei, Sarah Hawley, et al.
The Journal of Urology|December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK TrialNeal D Shore, Martin Gleave, Ugo De Giorgi, et al.
The Prostate|May 6, 2015
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancerDean A Troyer, Tamara Jamaspishvili, Wei Wei, et al.
BMC Urology|September 12, 2018
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet, Armen Aprikian, Alain Bergeron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
Pageof 26

Showing results (191-200 of 259) with videos related to

Sort By:
Pageof 26
Plos Medicine|July 3, 2019
Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker NetworkAndrée-Anne Grosset, Véronique Ouellet, Christine Caron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2018
Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate CancerMarine F Garrido, Nicolas J-P Martin, Matthieu Bertrand, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
The Journal of Clinical Investigation|December 18, 2019
Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor modelsLucia Nappi, Adeleke H Aguda, Nader Al Nakouzi, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
Plos One|July 15, 2015
Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 PatientsJames D Brooks, Wei Wei, Sarah Hawley, et al.
The Journal of Urology|December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK TrialNeal D Shore, Martin Gleave, Ugo De Giorgi, et al.
The Prostate|May 6, 2015
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancerDean A Troyer, Tamara Jamaspishvili, Wei Wei, et al.
BMC Urology|September 12, 2018
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet, Armen Aprikian, Alain Bergeron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
Pageof 26